Navigation Links
Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use

PROVIDENCE, R.I. A new study from Rhode Island Hospital researchers suggests that controlling cholesterol may be important for heart health in patients who are taking non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen. The findings are based on a study on the safety of NSAID medications in clinically relevant animal models when high cholesterol is a factor. The study is published in the current issue of the journal Surgery.

NSAIDs are among the most widely-used drugs today for the treatment of post-operative pain, inflammatory conditions and fever. Despite that, the factors that affect their cardiovascular safety are not well understood and some studies suggest that there may be an increased incidence of cardiovascular complications such as heart attack or death.

This study, led by principal investigator Frank Sellke, M.D., chief of cardiothoracic surgery and research at Rhode Island Hospital, developed an animal model of hypercholesterolemia in swine to investigate the formation of collateral vessels and other effects in the heart, and the safety of NSAID and other medications.

Through their study, Sellke says, "We found that a high-cholesterol diet reduced blood flow to the heart muscle in our animal models with chronic heart disease when given daily naproxen. We also found reduced levels of prostacyclin, a compound that dilates blood vessels and prevents blood clots. These findings suggest that there may be a stronger risk of negative effects on the heart in patients who have high cholesterol levels and are taking NSAIDs as a form of pain or inflammation relief."

The researchers compared two groups within the animal model, one with a normal diet, and one group that received a diet high in cholesterol, and both groups received daily naproxen. The animals also underwent surgery to simulate coronary artery disease, which affects many human patients who take NSAIDs. Several differences were found between the two groups.

Compared to animals with normal cholesterol, the high-cholesterol animals treated with naproxen had lower blood flow to the heart, decreased levels of prostacyclin, and decreased levels of several proteins that promote cardiac cell survival. In addition, previous studies by the group showed that while naproxen helped increased blood flow in the hearts of animals with normal cholesterol, this effect was not seen in animals with high cholesterol.

Sellke says, "These results show that high blood cholesterol levels change the way naproxen affects the heart, and alters blood flow to the heart. This 'myocardial perfusion' may be one predictor of angina frequency and quality of life in patients with chronic ischemia. Thus, these findings may have important implications for cardiac patients taking NSAIDs."

First author Louis Chu, M.D., who worked with Sellke on the study, adds, "Our study indicates that physicians should be aware that cholesterol control may be especially important if patients are taking NSAID medications such as naproxen."

Sellke adds, "While the results of these animal experiments are interesting and may provide information regarding the effect of a high fat diet on the response to naproxen and other similar medications, one cannot make definitive statements on the effect of these medications on patients without first doing clinical studies."


Contact: Nancy Jean

Related medicine news :

1. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
2. Rhode Island Hospital physician receives national award for research
3. Women & Infants launches Rhode Island Network for Pelvic Floor Disorders
4. Paper by Rhode Island Hospital physician selected among best of 2010 by JACR
5. Rhode Island Hospital fellow receives funding to support research in myocardial perfusion
6. Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals
7. Rhode Island Hospital study identifies fish oils impact on cognition and brain structure
8. Tishman Speyer Hosts Government, Union and Civic Leaders for Topping Out of Gotham Center Tower in Long Island City
9. Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers
10. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
11. Long Island Children's Orthodontist Announces Office Improvements And New Staff Member
Post Your Comments:
Related Image:
Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology: